This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Serena, C.
Right arrow Articles by Guarro, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Serena, C.
Right arrow Articles by Guarro, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*AMPHOTERICIN B

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2008, p. 1529-1532, Vol. 52, No. 4
0066-4804/08/$08.00+0     doi:10.1128/AAC.01097-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

In Vitro Interactions of Micafungin with Amphotericin B against Clinical Isolates of Candida spp.{triangledown}

Carolina Serena,1 Marçal Mariné,1 Guillermo Quindós,2 Alfonso J. Carrillo,3 J. F. Cano,1 F. Javier Pastor,1 and Josep Guarro1*

Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Reus, Spain,1 Departamento de Inmunología, Microbiología y Parasitología, Facultad de Medicina y Odontología, Universidad del País Vasco, Bilbao, Spain,2 Departamento de Microbiología, Asesoría Científica y de Investigación Aplicada, Barcelona, Spain3

Received 21 August 2007/ Returned for modification 10 November 2007/ Accepted 20 January 2008

The in vitro activity of amphotericin B in combination with micafungin was evaluated against 115 isolates representing seven species of Candida. Overall, the percentages of synergistic interactions were 50% and 20% when the MIC-2 (lowest drug concentration to cause a prominent reduction in growth) and MIC-0 (lowest drug concentration to cause 100% growth inhibition) end point criteria, respectively, were used. Antagonism was not observed. Some of the interactions were confirmed by time-kill assays.

* Corresponding author. Mailing address: Unitat de Microbiologia, Facultat de Medicina, Universitat Rovira i Virgili, Carrer Sant Llorenç, 21.43201 Reus, Spain. Phone: 977-759359. Fax: 977-759322. E-mail: josep.guarro{at}urv.cat

{triangledown} Published ahead of print on 28 January 2008.

Antimicrobial Agents and Chemotherapy, April 2008, p. 1529-1532, Vol. 52, No. 4
0066-4804/08/$08.00+0     doi:10.1128/AAC.01097-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Pai, M. P. (2009). Antifungal Combinations against Simulated Candida albicans Endocardial Vegetations. Antimicrob. Agents Chemother. 53: 2629-2631 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»